Zacks Investment Research
28 Sept 2026, 16:55 UTC · 55m ago
Verdict
Headline takes no side. We score OPK +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
OPK predicts bottom-line growth of 23.3% for 2026.
Priced inanalysis of existing guidance
So whatThis growth rate suggests a significant EPS increase relative to 2025, which may justify a higher P/E multiple if targets are met by year-end.
More positive than 79% of claims this week
The company has a market capitalization of $1.22 billion.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inpublic market data
More positive than 46% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company is described as well-positioned for growth with strong product performance and positive earnings surprises.
More positive than 57% of ticker scores this week
Mentioned positively regarding the global expansion and consistent growth of NGENLA.
More positive than 51% of ticker scores this week
Mentioned as a partner providing royalty potential through mazdutide.
More positive than 51% of ticker scores this week
Mentioned as a collaborator creating opportunities for future milestone payments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 35% of relationship scores this week
[mutual] OPKO Health receives royalty and profit-share income from Pfizer's commercialization of NGENLA.
More positive than 14% of relationship scores this week
[mutual] OPKO Health has a collaboration with Regeneron involving ModeX for potential milestone payments and royalties.
−0.6%
Price is moving against the score
$1.63 vs $1.64 close before publication (Sep 25) · not market-adjusted
OPK chart →
